摘要
钠-葡萄糖共转运体2抑制剂(SGLT-2i)是已被众多指南推荐用于成人2型糖尿病(T2DM)治疗的新型口服降糖药,该药在改善患者心血管结局和减缓糖尿病肾病(DKD)进展方面表现优异,同时还兼具减重、低血糖风险低等优势,因此,SGLT-2i在T2DM患者中的使用逐渐频繁,也必将越来越多地用于初级保健和非糖尿病专科之中。但SGLT-2i使用不当可能增加患者泌尿生殖道感染、糖尿病酮症酸中毒(DKA)、截肢与骨折、低血压甚至急性肾损伤风险。因此在基层医疗机构实践中规范SGLT-2i的使用,提出符合基层实际的、适合非专科医生临床实践的推荐或建议很有必要。
Sodium-glucose cotransporter 2 inhibitors(SGLT-2i)are a new oral hypoglycemic drug recommended by many guidelines for the treatment of adult type 2 diabetes(T2DM).They not only have excellent performance in improving cardiovascular outcome and slowing down the progression of diabetic kidney disease(DKD),but also have the advantages of weight loss and low risk of hypoglycemia.Therefore,SGLT-2i are prescribed more and more frequently for treating T2DM patients,and will also be increasingly used by primary care doctors and non-diabetes specialties.However,improper use of SGLT-2i may increase the risk of genitourinary tract infection,diabetic ketoacidosis(DKA),amputation and fracture,hypotension,and even acute renal injury.Therefore,it is necessary to standardize the use of SGLT-2i in basal level medical facilities and put forward recommendations or suggestions that are in line with the reality of basal level medical facilities and suitable for the clinical practice of non-specialists for T2DM.
出处
《中国医师杂志》
CAS
2022年第8期1153-1159,共7页
Journal of Chinese Physician
基金
深圳市卫生健康委员会医防融合项目资助课题(深卫健体改-2019-25)。
关键词
糖尿病
2型
钠-葡萄糖共转运体2抑制剂
基层医疗机构
Diabetes mellitus,type 2
Sodium-glucose cotransporter 2 inhibitors
Basic level medical facilities
